Theme Member
Professor Geraint Rogers


Director, Microbiome Research, SAHMRI

Professor, Flinders University School of Medicine

Matthew Flinders Research Fellow


Phone: 08 8204 7614



Bachelor of Science (Hons): Molecular Microbiology, University of Edinburgh, Scotland. 1999

PhD: Molecular Genetics, King’s College London, 2004


Prof Rogers is a molecular microbiologist and microbial ecologist. He is the Director, Microbiome Research at SAHMRI, leads a laboratory based within the Flinders University School of Medicine, and is supported by a Matthew Flinders Research Fellowship. His research programme focuses on the contribution of human-associated microbiota to health and disease. 

Geraint's Group Members

Selected publications 

Lynn M, Tumes, D, Blake S, Sribnaia A, Choo J Leong LEX, Wesselingh SL, Marshall H, Rogers GB, Lynn DL. Early-life antibiotic-driven dysbiosis in mice leads to impaired antibody responses and enhanced T cell cytokine recall responses to vaccines that are routinely administered to infants worldwide. Cell Host Microbe. 2018 May 9;23(5):653-660.

Choo JM, Guy Abell CJ, Thomson R, Morgan L, Waterer G, Gordon DL, Taylor SL, Leong LEX, Wesselingh SL, Burr LD, Rogers GB. The impact of long-term erythromycin therapy on the oropharyngeal microbiome and resistance gene reservoir in non-cystic fibrosis bronchiectasis. mSphere. 2018. Apr 18;3(2). pii: e00103-18.

Taylor SL, Leong LEX, Choo JM, Wesselingh S, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, Baraket M, Marks GB, Gibson PG, Simpson JL, Rogers GB. Inflammatory phenotypes in severe asthma are associated with distinct airway microbiology. Journal of Allergy and Clinical Immunology. 2018. 141(1):94-103.e15.

Rogers GB. Inflammation, age, and changing microbiology: the search for causation in the cystic fibrosis airways. European Respiratory Journal. 2017. 50(5). pii: 1701935..

Kvasnovsky CL, Leong LEX, Choo JM, Abell GCJ, Papgrigoriadis S, Bruce KD, Rogers GB. Clinical and symptom scores are significantly correlated with microbiota features in patients with symptomatic uncomplicated diverticular disease - A pilot study. European Journal of Gastroenterology & Hepatology. 2017. 30(1):107-112.

Leong LEX, Taylor SL, Shivasami A, Goldwater P, Rogers GB. Intestinal Microbiota Composition in Sudden Infant Death Syndrome and Age-matched Controls. Journal of Pediatrics. 2017 191:63-68.e1.

Cathie K, Howlin RP, Hall-Stoodley L, Cornelius P, Duignan C, Allan R, Feelisch M, Fernandez BO, Barraud N, Bruce KD, Jefferies J, Kelso M, Kjelleberg S, Rice S, Rogers GB, Pink S, Smith C, Sukhtankar P, Salib R, Legg J, Carroll M, Daniels T, Stoodley P, Clarke S, Connett G, Faust S, Webb J. Low dose nitric oxide as adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis: a proof of concept clinical trial. Molecular Therapy. 2017;25(9):2104-2116

Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, Marks GB, Baraket M, Powell H, Taylor SL, Leong LEX, Rogers GB, Simpson JL. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. The Lancet. 2017. 390(10095):659-668.

Choo JM, Trim P, Leong LEX, Abell G, Brune C, Jeffries N, Wesselingh SL, Dear N, Snel M, Rogers GB. Inbred mouse populations exhibit substantial intergenerational changes in intestinal microbiota composition and function following introduction to a facility. Frontiers in Microbiology. 2017; 8:608.

Choo JM, Kanno T, Zain NMM, Leong LEX, Abell GCJ, Keeble JE, Bruce KD, Mason AJ, Rogers GB. Divergent relationships between faecal microbiota and metabolome following distinct antibiotic-induced disruptions. mSphere. 2017. 2(1): e00005-17.

Taylor SL, Woodman RJ, Chen A C-H, Burr LD, Gordon DL, McGuckin MA, Wesselingh S, Rogers GB. Culture-Independent FUT2 genotype influences lung function, exacerbation frequency, and airway microbiota in non-CF bronchiectasis. Thorax. 2016;72(4):304-310.

Scoleri GP, Choo JM, Leong LEX, Goddard TR, Shephard L, Burr LD, Bastian I, Thomson RM, Rogers GB. Culture-Independent Detection of Nontuberculous Mycobacteria in Clinical Respiratory Samples. Journal of Clinical Microbiology. 2016 Sep;54(9):2395-8.

Rogers GB, Keating DJ, Young RL, Wong ML, Licinio J, Wesselingh S. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Molecular Psychiatry. 2016 Jun;21(6):738-48.

Wong ML, Inserra A, Lewis M, Mastronardi CA, Leong L, Choo J, Kentish S, Xie P, Morrison M, Wesselingh S, Rogers GB, Licinio J. Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition. Molecular Psychiatry. 2016 Jun;21(6):797-805.

Rogers GB, Wesselingh S. Precision Respiratory Medicine and the Microbiome. Lancet Respiratory Medicine. 2016 Jan;4(1):73-82.

Cuthbertson L, Rogers GB, Walker A, Oliver A, Green L, Daniels TWV, Carroll, MP, Parkhill, J, Bruce KD, van der Gast CJ. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention. ISME J. 2015;10(5):1081-91.

Rogers GB. Germs and joints: the contribution of the human microbiome to rheumatoid arthritis. Nature Medicine. 2015: 21(8):839-41.

Jervis-Bardy J, Leong LEX, Marri S, Smith RJ, Choo JM, Smith-Vaughan HC, Nosworthy E, Morris PS, O’Leary S, Rogers GB* Marsh RL Deriving accurate microbiota profiles from human samples with low bacterial content through post-sequencing processing of Illumina MiSeq data. Microbiome. 2015. 3:19.

Hedin C, van der Gast CJ, Rogers GB, Cuthbertson L, McCartney S, Stagg AJ, Lindsay JO, Whelan K. Crohn's disease siblings exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities. Gut. 2015. Jun;65(6):944-53.

Boyd MA, Donovan B, Prestage G, Chen M, Petoumenos K, Gray R, Guy R, Rogers GB, Bourne C, Klausner JD. Is it time to rethink syphilis control? Clinical Infectious Diseases. 2014 60(2):325-6.

Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respiratory Medicine. 2014 2(12):988-96.

Rogers GB, Bruce KD, Marsh RL, Carroll MP, Serisier DJ, Shaw D. Respiratory microbiota – addressing clinical questions, informing clinical practice. Thorax. 2014. 70(1):74-81.

Rogers GB, van der Gast CJ, Serisier DJ. Predominant pathogen competition and core microbiota divergence in chronic airway infection. ISME J. 2014. 9(1):217-25. Corresponding author.

Rogers GB, van der Gast CJ, Cuthbertson L, SK, Bruce KD, Martin ML, Serisier DJ. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax. 2013 68:731-7.

Wolter DJ, Emerson JC, McNamara S, Buccat AM, Cochrane E, LS Houston, Rogers GB, P Marsh, K Prehar, CE Pope, M Blackledge, E Déziel, KD Bruce, Bonnie Ramsey, RL Gibson, JL Burns, LR Hoffman. Staphylococcus aureus small-colony variants are independently associated with advanced lung disease in children with cystic fibrosis. Clinical Infectious Diseases. 2013 57:384-91.

Rogers GB, van der Gast CJ, Hoffman LR, Cutherbertson L, Wing P, Pope C, Hooftman D, Lilley AK, Carroll MP, Bruce KD. Towards unbiased bacterial community analysis in lower respiratory infections. ISME J. 2012. 1–10

Stressmann AF, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, Hoffman LR, Daniels TWV, Patel N, Forbes B, Bruce KD. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the cystic fibrosis lung are stable and resilient. Thorax. 2012 67(10):867-73. Corresponding Author

van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Daniels TWV, Carroll MP, Parkhill J, Bruce KD. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. 2010, ISME 5(5):780-91.

Selected current funding

Medical Research Future Fund. A metagenome-wide approach to characterise the carriage and transmission of antimicrobial resistance genes in residential aged care facilities. 2018-2021. Principal Investigator. $1,414,000.

NHMRC Project Grant - APP1104000. Long-term macrolide therapy; oropharyngeal dysbiosis and the spread of resistant pathogens (CIA) $384,152.50 2016-2019.

NHMRC Project Grant - APP1098429. The impact of the neonatal gut microbiome on specific and nonspecific vaccine responses (CIB) $661,495.50 2016-2019.

NHMRC Project Grant - APP1102494. The emerging problem of non-tuberculous mycobacteria infection: understanding aetiology, geospatial epidemiology and developing interventions (CIB) $988,791.40 2016-2021.

NHMRC Project Grant - APP1108422. How does dietary cholesterol induce non-alcoholic steatohepatitis? (CIB) 2016-2019. $855,972.

NHMRC Centre for Research Excellence. Targeted Nutrition to Improve Maternal and Child Health Outcomes. 2017-2021 Assoc. Investigator. $2,500,000.

NHMRC Centre for Research Excellence. SCALE-C: Strategies for hepatitis C testing and treatment in Aboriginal communities that Lead to Elimination. 2018-2022. Assoc. Investigator $2,145,138.

NHMRC Project Grant - APP1044829 Clinical and psychosocial changes over late childhood and adolescence and early life determinants of long term clinical outcomes in cystic fibrosis. (CIE) 2013-2015. $1,135,570.31.

Bill & Melinda Gates Foundation - ‎Grand Challenges: Seed Grant. An intergenerational prebiotic approach to establishment of a healthy colonic microbiome in infants. $680,986.

Medical Research Future Fund. A platform clinical trial approach to the management of Mycobacterium abscessus complex. 2018-2022. Investigator. $5,000,000

Cystic Fibrosis Research, Incorporated (CFRI). Bacterial community‐level susceptibility testing for CF lung infections. 2019-2020. $181,105.

The Hospital Research Foundation – Royal Adelaide Hospital Translational Grants. A bitter tale of artificial sweeteners in Type 2 diabetes? 2018-2020. Investigator. $250,000.

Almond Board of California. Does inclusion of almonds in an energy restricted diet enhance weight loss and protect against weight regain? $1,546,438.

Mead Johnson Nutritionals: A Randomized Controlled Trial to Investigate Nutritive Effects of A Cow's Milk-Based Infant Formula on Growth Rates of Late Preterm Infants (The GaINS Trial). 2017-2020. Investigator. $2,275,261.

Get in touch
+61 8 8128 4000
You can't miss us!
North Terrace Adelaide 5000 South Australia
Postal Address
PO BOX 11060 Adelaide 5001 South Australia
Key Partners
SAHMRI is located on the traditional lands of the Kaurna Nation.

The SAHMRI community acknowledges and respects the traditional owners, the family clans who are the Kaurna Nation from the Adelaide Plains region of South Australia. We acknowledge the clans of the Kaurna Nation and the sacred knowledge they hold for their country. We pay our respects to the Kaurna Nation, their ancestors and the descendants of these living family clans today.